Base de dados : LILACS
Pesquisa : D12.644.456 [Categoria DeCS]
Referências encontradas : 53 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 53 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Srougi, Miguel
Texto completo
Id: biblio-975631
Autor: Mattiolli, Aline B; Santos, Allan; Vicente, Andreia; Queiroz, Marcelo; Bastos, Diogo; Herchenhorn, Daniel; Srougi, Miguel; Peixoto, Fabio A; Morikawa, Lisa; Silva, João Luiz Fernandes da; Etchebehere, Elba.
Título: Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study
Fonte: Int. braz. j. urol;44(5):892-899, Sept.-Oct. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: The purpose of our study was to evaluate the clinical impact of 68Ga-PSMA PET / CT in the setting of biochemical recurrence of prostate cancer. Materials and Methods: We retrospectively evaluated 125 prostate cancer patients submitted to the 68Ga-PSMA PET / CT due to biochemical recurrence. The parameters age, Gleason score, PSA levels, and the highest SUVmax were correlated to potential treatment changes. The highest SUVmax values were correlated with age and Gleason score. The median follow-up time was 24 months. Results: 68Ga-PSMA PET / CT led to a treatment change in 66 / 104 (63.4%) patients (twenty-one patients were lost to follow-up). There was a significant change of treatment plan in patients with a higher Gleason score (P = 0.0233), higher SUVmax (p = 0.0306) and higher PSA levels (P < 0.0001; median PSA = 2.55 ng / mL). Conclusion: 68Ga-PSMA PET / CT in prostate cancer patients with biochemical recurrence has a high impact in patient management.
Descritores: Oligopeptídeos
Neoplasias da Próstata/sangue
Neoplasias da Próstata/diagnóstico por imagem
Ácido Edético/análogos & derivados
Antígeno Prostático Específico/sangue
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos
Recidiva Local de Neoplasia/diagnóstico por imagem
-Neoplasias da Próstata/terapia
Estudos Retrospectivos
Seguimentos
Sensibilidade e Especificidade
Gradação de Tumores
Pessoa de Meia-Idade
Recidiva Local de Neoplasia/terapia
Limites: Humanos
Masculino
Adulto
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Estudo Multicêntrico
Responsável: BR1.1 - BIREME


  2 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1012312
Autor: Leitsmann, Conrad; Thelen, Paul; Schmid, Marianne; Meller, Johannes; Sahlmann, Carsten-Oliver; Meller, Birgit; Trojan, Lutz; Strauss, Arne.
Título: Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
Fonte: Int. braz. j. urol;45(3):459-467, May-June 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: 68Ga-PSMA PET/CT imaging is a promising modality for the staging of recurrent prostate cancer (PCa). Current evidence suggests limited diagnostic value of the 68Ga-PSMA PET/CT in PSA-levels ≤0.3ng/mL. Experimental data have demonstrated an increase in PSMA-expression in PCa metastases by androgen deprivation in vitro. The aim of the current study was to investigate a possible enhancing effect of PSMA with low-dose androgen deprivation in patients with BCR and low PSA-levels. Materials and Methods: Five patients with PCa and BCR, following radical prostatectomy, underwent 68Ga-PSMA PET/CT. A consecutive 68Ga-PSMA PET/CT was performed 6 to 11 days after injection of 80mg of Degarelix (Firmagon®). We recorded PSA and testosterone serum-levels and changes of PSMA-uptake in 68Ga-PSMA PET/CT images. Results: Median PSA prior 68Ga-PSMA PET/CT was 0.27ng/mL. All patients had a decrease in testosterone serum levels from median 2.95μg/l to 0.16μg/l following Degarelix injection. We observed an increase in the standardized uptake value (SUV) in PSMA-positive lymphogenous and osseous lesions in two patients following androgen deprivation. In another two patients, no PSMA positive signals were detected in either the first or the second scan. Conclusion: Our preliminary results of this feasibility assessment indicate a possible enhancing effect of PSMA-imaging induced by low-dose ADT. Despite several limitations and the small number of patients, this could be a new approach to improve staging by 68Ga-PSMA PET/CT in PCa patients with BCR after primary therapy. Further prospective studies with larger number of patients are needed to validate our findings.
Descritores: Compostos Organometálicos
Neoplasias da Próstata/patologia
Glicoproteínas de Membrana
Compostos Radiofarmacêuticos
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos
Antagonistas de Androgênios/uso terapêutico
Metástase Neoplásica/diagnóstico por imagem
-Oligopeptídeos/uso terapêutico
Valores de Referência
Fatores de Tempo
Reprodutibilidade dos Testes
Antígeno Prostático Específico/sangue
Gradação de Tumores
Pessoa de Meia-Idade
Recidiva Local de Neoplasia/patologia
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  3 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1134336
Autor: Yamaga, Lilian Yuri Itaya; Cunha, Marcelo Livorsi da.
Título: Atypical metastases from prostate cancer detected on 68Ga-PSMA PET/CT: a case series
Fonte: Int. braz. j. urol;47(1):205-209, Jan.-Feb. 2021. graf.
Idioma: en.
Descritores: Compostos Organometálicos
Neoplasias da Próstata/diagnóstico por imagem
-Oligopeptídeos
Glicoproteínas de Membrana
Ácido Edético/análogos & derivados
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
Limites: Humanos
Masculino
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  4 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Souto, Francisco José Dutra
Texto completo
Id: biblio-897052
Autor: Lobato, Cirley Maria de Oliveira; Balassiano, Natalia; Hyppolito, Elodie Bomfim; Sanchez-Lermen, Rafaela Liz Pellegrim; Signorelli, Izabelle Venturini; Nicacio, Miguel Yasuo Tomita; Firmino Filho, Alberto Pereira; Andrade, Thais Guaraná de; Lima, José Milton de Castro; Arruda, Talita Amorim de; Coutinho, Fernanda Schwanz; Araujo, Everton Felipe do Vale; Esmeraldo, Ticiana Mota; Cortez, Erlon; Capeli, Rafaela Lorenzon Aragão; Matos, Melquior Brunno Mateus de; Pessoa, Francisco Sérgio Rangel; Oliveira, Hélder Cássio de; Arruda, Érico Antônio Gomes de; Gonçalves, Patrícia Lofêgo; Araújo Filho, Antônio Haroldo; Esberard, Eliane Bordalo Cathalá; Souto, Francisco José Dutra.
Título: Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil
Fonte: Rev. Soc. Bras. Med. Trop;51(1):14-20, Jan.-Feb. 2018. tab.
Idioma: en.
Resumo: Abstract INTRODUCTION: In 2013, combination therapy using peginterferon, ribavirin, and boceprevir or telaprevir was introduced to treat hepatitis C virus genotype 1 infection in Brazil. The effectiveness of this therapy in four Brazilian regions was evaluated. METHODS: Clinical and virological data were obtained from patients of public health institutions in five cities, including sustained virological response (SVR) and side effects. Patients with advanced fibrosis (F3/4), moderate fibrosis (F2) for > 3 years, or extra-hepatic manifestations were treated according to Ministry of Health protocol. Treatment effectiveness was verified by using bivariate and multivariate analysis; p-values of < 0.05 were considered significant. RESULTS: Of 275 patients (64.7% men; average age, 57 years old), most (61.8%) were treatment-experienced; 53.9% had subgenotype 1a infection, 85.1% had advanced fibrosis, and 85.5% were treated with telaprevir. SVR was observed in 54.2%. Rapid virological response (RVR) was observed in 54.6% of patients (data available for 251 patients). Overall, 87.5% reported side effects and 42.5% did not complete treatment. Skin rash, severe infection, and death occurred in 17.8%, 2.5%, and death in 1.4% of cases, respectively. SVR was associated with treatment completion, RVR, and anemia. CONCLUSIONS: The effectiveness of hepatitis C virus triple therapy was lower than that reported in phase III clinical trials, possibly owing to the prioritized treatment of patients with advanced liver fibrosis. The high frequency of side effects and treatment interruptions observed supported the decision of the Brazilian authorities to suspend its use when safer and more effective drugs became available in 2015.
Descritores: Inibidores de Proteases/administração & dosagem
Hepacivirus/genética
Hepatite C Crônica/tratamento farmacológico
-Oligopeptídeos/administração & dosagem
Ribavirina/administração & dosagem
Prolina/administração & dosagem
Prolina/análogos & derivados
Protocolos Clínicos
Interferons/administração & dosagem
Resultado do Tratamento
Hepatite C Crônica/virologia
Quimioterapia Combinada
Resposta Viral Sustentada
Genótipo
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adulto
Idoso
Tipo de Publ: Estudo Multicêntrico
Ensaio Clínico Fase III
Responsável: BR1.1 - BIREME


  5 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Villanova, Marcia Guimaräes
Martinelli, Ana de Lourdes Candolo
Texto completo
Id: biblio-897067
Autor: Chachá, Silvana Gama Florencio; Rodrigues, João Paulo Vilela; Araújo, Roberta Chaves; Pereira, Leonardo Régis Leira; Villanova, Márcia Guimarães; Souza, Fernanda Fernandes; Santana, Rodrigo de Carvalho; Martinelli, Ana de Lourdes Candolo.
Título: First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
Fonte: Rev. Soc. Bras. Med. Trop;51(2):146-154, Mar.-Apr. 2018. tab, graf.
Idioma: en.
Resumo: Abstract INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center. METHODS: A retrospective descriptive study was conducted in patients with HCV genotype 1 infection who started treatment between July 2013 and December 2015. Data were collected using a computerized system. RESULTS: A total of 115 subjects were included, of which 58 (50.4 %) had liver cirrhosis and 103 (89.6 %) used TVR. The overall SVR rate was 61.7 % (62.1 % for TVR and 58.3 % for BOC). The presence of cirrhosis was associated with a lower SVR rate, whereas patients who relapsed after prior therapy had a greater chance of showing SVR than did non-responders. The incidence of adverse drug reactions (ADRs) was high. Almost all patients (~100 %) presented with hematologic events. Furthermore, treatment had to be discontinued in 15 subjects (13 %) due to severe ADRs. CONCLUSIONS: In conclusion, the SVR rates in our study were lower than those reported in pre-marketing studies but were comparable to real-life data. ADRs, particularly hematological ADRs, were more common compared to those in previous studies and resulted in a high rate of treatment discontinuity.
Descritores: Antivirais/administração & dosagem
Inibidores de Proteases/administração & dosagem
Hepacivirus/genética
Hepatite C Crônica/tratamento farmacológico
-Oligopeptídeos/administração & dosagem
Oligopeptídeos/efeitos adversos
Antivirais/efeitos adversos
Polietilenoglicóis/administração & dosagem
Polietilenoglicóis/efeitos adversos
Inibidores de Proteases/efeitos adversos
Ribavirina/administração & dosagem
Ribavirina/efeitos adversos
Proteínas Recombinantes/administração & dosagem
Proteínas Recombinantes/efeitos adversos
Prolina/administração & dosagem
Prolina/análogos & derivados
Prolina/efeitos adversos
Estudos Retrospectivos
Resultado do Tratamento
Interferon-alfa/administração & dosagem
Interferon-alfa/efeitos adversos
Hepacivirus/efeitos dos fármacos
Hepatite C Crônica/genética
Hepatite C Crônica/virologia
Quimioterapia Combinada
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Interferon alfa-2
Genótipo
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adulto
Idoso
Responsável: BR1.1 - BIREME


  6 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Machado, Paulo Eduardo de Abreu
Texto completo
Id: biblio-977101
Autor: Winckler, Fernanda Cristina; Braz, Aline Marcia Marques; Silva, Vanessa Nogueira da; Golim, Marjorie de Assis; Andrade, Vanessa Gutierrez de; Machado, Paulo Eduardo de Abreu; Silveira, Liciana Vaz de Arruda; Silva, Giovanni Faria.
Título: Influence of the inflammatory response on treatment of hepatitis C with triple therapy
Fonte: Rev. Soc. Bras. Med. Trop;51(6):731-736, Nov.-Dec. 2018. tab.
Idioma: en.
Resumo: Abstract INTRODUCTION: Chronic hepatitis C is a leading cause of liver disease. Infection triggers an immediate immune response in the host that is mediated by humoral/cellular mechanisms. T cells respond to infection via secretion of cytokines, which inhibit or stimulate one another, leading to cytokine imbalance and ultimately affecting treatment. Studies using interferon (IFN) and ribavirin (RBV) showed that TCD8+ cells and cytokine levels are associated with sustainable virological response (SVR). However, studies that investigated the effects of triple therapy (TT) are limited. METHODS: The study included hepatitis C virus (HCV)+ RNA, naives, genotype 1, ≥18 years, and advanced fibrosis (F≥3) patients. Samples were collected at baseline and after 12 weeks (W12) of TT. Six cytokines were analyzed by flow cytometry. RESULTS: Of 31 patients, four were excluded (two deaths, one interrupted TT, and one F2 patient). Of the 27 remaining patients, 21 (78%) were cirrhotic. SVR was achieved in 63% of the patients. The patients had a mean age of 55.11 ± 10.03 years. Analyses at baseline showed that the chemokine CCL5/Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) (p=0.04) and interleukin (IL)-6 (p=0.02), which was associated with SVR. RANTES (p=0.04) and IL-8 (p=0.01) levels were associated with SVR at W12. CONCLUSIONS Similar to patterns observed during double therapy, IL-6, IL-8, and RANTES levels were associated with SVR in TT, indicating the potential role of interferon in immune response to hepatitis C virus.
Descritores: Oligopeptídeos/administração & dosagem
Antivirais/administração & dosagem
Prolina/análogos & derivados
Citocinas/sangue
Hepatite C Crônica/tratamento farmacológico
-Prolina/administração & dosagem
Estudos Prospectivos
Resultado do Tratamento
Carga Viral
Hepatite C Crônica/sangue
Quimioterapia Combinada
Citometria de Fluxo
Genótipo
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Responsável: BR1.1 - BIREME


  7 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-767809
Autor: Fagundes, Raíssa Neves; Ferreira, Lincoln Eduardo Villela Vieira de Castro; Pace, Fábio Heleno de Lima.
Título: Health-Related Quality of Life in patients with hepatitis C in double and triple therapy / Calidad de vida relacionada con la salud en pacientes con hepatitis c en terapia doble y triple / Qualidade de vida relacionada à saúde em pacientes com hepatite C em terapia dupla e tripla
Fonte: Rev. Esc. Enferm. USP;49(6):937-943, Dec. 2015. graf.
Idioma: pt.
Resumo: Abstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.

Resumen OBJETIVO Comparar los puntajes de Calidad de Vida Relacionada con la Salud (CVRS) en pacientes con hepatitis C crónica sometidos a la terapia antiviral doble y triple y analizar los posibles factores relacionados con la CVRS. MÉTODO La CVRS fue evaluada utilizando el Short Form 36 y elChronic Liver Disease Questionnaire , que fueron aplicados antes y en las semanas 4, 12 y 16 de tratamiento, en 32 pacientes divididos en 2 grupos: terapia doble con interferón pegilado (IFN-PEG) y ribavirina, y triple con IFN-PEG, ribavirina y telaprevir. RESULTADOS La reducción de la CVRS fue mayor en pacientes en terapia triple cuando comparados con los tratados con dos drogas, siendo el momento más crítico la 12ª semana en ambos grupos. Después de la retirada del telaprevir, el grupo de terapia triple mejoró de modo significativo los puntajes de CVRS. Ansiedad y depresión en el pre tratamiento, situación de empleo y raza se mostraron relacionados con la reducción de la CVRS. CONCLUSIÓN Pacientes sometidos a la terapia doble y triple presentan reducción de los índices de CVRS, pero la adición del telaprevir les proporciona una caída más expresiva.

Resumo OBJETIVO Comparar os escores de Qualidade de Vida Relacionada à Saúde (QVRS) em pacientes com hepatite crônica C submetidos à terapia antiviral dupla e tripla e analisar os possíveis fatores relacionados à QVRS. MÉTODO A QVRS foi avaliada utilizando o Short Form 36 e oChronic Liver Disease Questionnaire , que foram aplicados antes e nas semanas 4, 12 e 16 de tratamento, em 32 pacientes divididos em 2 grupos: terapia dupla com interferon peguilado (IFN-PEG) e ribavirina e tripla com IFN-PEG, ribavirina e telaprevir. RESULTADOS A redução da QVRS foi maior em pacientes em terapia tripla quando comparados àqueles tratados com duas drogas, sendo o momento mais crítico a 12ª semana em ambos os grupos. Após a retirada do telaprevir, o grupo terapia tripla melhorou de modo significativo os escores de QVRS. Ansiedade e depressão no pré-tratamento, status empregatício e raça se mostraram relacionados à redução da QVRS. CONCLUSÃO Pacientes submetidos à terapia dupla e tripla apresentam redução dos índices de QVRS, mas a adição do telaprevir confere uma queda mais expressiva.
Descritores: Antivirais/administração & dosagem
Hepatite C Crônica/tratamento farmacológico
Interferon-alfa/administração & dosagem
Oligopeptídeos/administração & dosagem
Polietilenoglicóis/administração & dosagem
Qualidade de Vida
Ribavirina/administração & dosagem
-Quimioterapia Combinada
Proteínas Recombinantes/administração & dosagem
Limites: Feminino
Humanos
Masculino
Responsável: BR1.1 - BIREME


  8 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Brandelli, Adriano
Texto completo
Id: biblio-886885
Autor: COSTA, GÉSSICA A; ROSSATTO, FERNANDA C P; MEDEIROS, ALINE W; CORREA, ANA PAULA F; BRANDELLI, ADRIANO; FRAZZON, ANA PAULA G; MOTTA, AMANDA DE S DA.
Título: Evaluation antibacterial and antibiofilm activity of the antimicrobial peptide P34 against Staphylococcus aureus and Enterococcus faecalis
Fonte: An. acad. bras. ciênc;90(1):73-84, Mar. 2018. tab.
Idioma: en.
Resumo: ABSTRACT The adhesion ability of bacteria to abiotic surfaces has important implications in food industries, because these organisms can survive for long periods through the biofilm formation. They can be transferred from one place to another in the industry causing contamination of the food processing environment. In this study, the antibacterial and antibiofilm activities of the antimicrobial peptide P34, characterized as a bacteriocin-like substance (BLS P34) were tested against planktonic and sessile cells of Staphylococcus aureus and Enterococcus faecalis isolated from foods. The BLS P34 showed inhibitory effect against all planktonic cells of E. faecalis. The inhibition of biofilm formation and the eradication of pre-formed biofilm were evaluated with the crystal violet assay and with the reduction of 3-bromide [4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium. The BLS P34 promoted a reduction of percentage of adhered microbial cells on the surface, not being able to perform the complete elimination of biofilm formation. The metabolic activity of S. aureus biofilms decreased considerably between 41-95%. However, E. faecalis cells showed up metabolically stimulated. The BLS P34 has the potential antibiofilm for the species S. aureus. Studies suggest more detailed approaches to a better understanding of the interactions between the antimicrobial and bacterial cells within the biofilm structure.
Descritores: Oligopeptídeos/farmacologia
Staphylococcus aureus/efeitos dos fármacos
Bacteriocinas/farmacologia
Enterococcus faecalis/efeitos dos fármacos
Biofilmes/efeitos dos fármacos
Antibacterianos/farmacologia
-Bacillus/isolamento & purificação
Bacillus/metabolismo
Bacteriocinas/isolamento & purificação
Aderência Bacteriana/efeitos dos fármacos
Testes de Sensibilidade Microbiana
Análise de Variância
Limites: Animais
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  9 / 53 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Marcon, Sônia Silva
Texto completo
Id: lil-732823
Autor: Rissardo, Leidyani Karina; Alvim, Neide Aparecida Titonelli; Marcon, Sonia Silva; Carreira, Lígia.
Título: Práticas de cuidado ao idoso indígena - atuação dos profissionais de saúde / The elderly care practices of indigenous-performance of health / Las prácticas de cuidado de ancianos indígenas de rendimiento de la salud
Fonte: Rev. bras. enferm;67(6):920-927, Nov-Dec/2014.
Idioma: pt.
Projeto: Fundação Araucária.
Resumo: Este estudo objetivou compreender as práticas de cuidado dos profissionais de saúde que assistem os idosos Kaingang. Estudo qualitativo, apoiado na etnografia, realizado com dez profissionais à que atuam na atenção primária saúde da Terra Indígena Faxinal, Paraná, Brasil. Os dados foram coletados no período de novembro de 2010 a fevereiro de 2012 por meio da observação participante e entrevistas, e, analisados à luz da Teoria Transcultural do Cuidado. Identificaram-se como práticas de cuidado a medicação e imunização, bem como, cuidados da medicina tradicional. Para realização destes cuidados, os profissionais dispunham de estratégias que proporcionavam manutenção dos idosos na assistência. Conclui-se que valores culturais e científicos necessitam integrar a assistência para melhoria da saúde dos idosos indígenas.

This research aims to understand the care practices of health professionals who assist the elderly Kaingang. It is a qualitative study, supported in ethnography, conducted by ten professionals working in primary health care in the indigenous land of Faxinal, Paraná, Brazil. The data was collected from November 2010 to February 2012 by participant observation and interviews, and analyzed based on the Transcultural Care Theory. Was identified the preoccupation of the carers practices with the medication and immunization, as well as traditional medical care. To achieve these, care professionals had strategies that implemented maintenance of older people in care. We conclude that cultural values and integrate scientific need assistance to improve the health of elderly indigenous.

Este estudio tuvo como objetivo entender las prácticas de cuidado de los profesionales de la salud que asisten a los ancianos Kaingang. Estudio cualitativo, apoyado en la etnografía, llevado a cabo con diez profesionales que trabajan en la atención primaria de la salud de la tierra indígena de Faxinal, Paraná, Brasil. Los datos fueron recogidos a partir de noviembre 2010 a febrero 2012 a través de la observación participante y las entrevistas, y analizado con base en la Teoría del Cuidado Transcultural. Se identificaron las prácticas de atención médica y imunizacion,el cuidado de la medicina, así tradicional. Para lograrlo, los profesionales tenían estrategias que proporcionaban el mantenimiento de las personas mayores en su atención. Se concluye que los valores culturales y científicos necesitan ayuda para mejorar la salud de los ancianos indígenas.
Descritores: Fígado/enzimologia
Lisossomos/enzimologia
Fosfolipases A/metabolismo
Fosfolipases/metabolismo
Inibidores de Proteases/farmacologia
-Células Cultivadas
Quimotripsina/antagonistas & inibidores
Inibidores de Cisteína Proteinase/farmacologia
Leucina/análogos & derivados
Leucina/farmacologia
Leupeptinas/farmacologia
Oligopeptídeos/farmacologia
Pepstatinas/farmacologia
Fosfolipases A1
Fatores de Tempo
Limites: Animais
Ratos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  10 / 53 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Coelho, Henrique Sérgio Moraes
Alvares-da-Silva, Mario Reis
Texto completo
Id: biblio-840088
Autor: Callefi, Luciana Azevedo; Villela-Nogueira, Cristiane Alves; de Barros Tenore, Simone; Carnaúba-Júnior, Dimas; Coelho, Henrique Sérgio Moraes; Pinto, Paulo de Tarso A; Nabuco, Letícia Cancella; Pessoa, Mário Guimarães; Ferraz, Maria Lucia Cardoso Gomes; Ferreira, Paulo Roberto Abrão; de Lourdes Candolo Martinelli, Ana; Chachá, Silvana Gama Florencio; de Souza Paiva Ferreira, Adalgisa; de Macedo Bisio, Alessandra Porto; Brandão-Mello, Carlos Eduardo; Álvares-Da-Silva, Mário Reis; Reuter, Tânia; Ivantes, Claudia Alexandra Pontes; de Mello Perez, Renata; Mendes-Correa, Maria Cássia Jacintho.
Título: Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study
Fonte: Clinics;72(6):378-385, June 2017. tab, graf.
Idioma: en.
Resumo: OBJECTIVE: To evaluate the effectiveness and safety of first-generation protease inhibitors for the treatment of genotype 1 hepatitis C virus-infected patients at Brazilian reference centers. METHODS: This multicenter cross-sectional study included hepatitis C virus genotype 1 monoinfected patients treated with Peg-interferon, ribavirin, and either boceprevir (n=158) or telaprevir (n=557) between July 2013 and April 2014 at 15 reference centers in Brazil. Demographic, clinical, virological, and adverse events data were collected during treatment and follow-up. RESULTS: Of the 715 patients, 59% had cirrhosis and 67.1% were treatment-experienced. Based on intention-to-treat analysis, the overall sustained viral response was 56.6%, with similar effectiveness in both groups (51.9% for boceprevir and 58% for telaprevir, p=0.190). Serious adverse events occurred in 44.2% of patients, and six deaths (0.8%) were recorded. Cirrhotic patients had lower sustained viral response rates than non-cirrhotic patients (46.9% vs. 70.6%, p<0.001) and a higher incidence of serious adverse events (50.7% vs. 34.8%, p<0.001). Multivariate analysis revealed that sustained viral response was associated with the absence of cirrhosis, viral recurrence after previous treatment, pretreatment platelet count greater than 100,000/mm3, and achievement of a rapid viral response. Female gender, age>65 years, diagnosis of cirrhosis, and abnormal hemoglobin levels/platelet counts prior to treatment were associated with serious adverse events. CONCLUSION: Although serious adverse events rates were higher in this infected population, sustained viral response rates were similar to those reported for other patient cohorts.
Descritores: Antivirais/administração & dosagem
Hepacivirus/genética
Hepatite C Crônica/tratamento farmacológico
Inibidores de Proteases/administração & dosagem
-Brasil
Estudos Transversais
Genótipo
Hepatite C Crônica/virologia
Interferon-alfa/administração & dosagem
Oligopeptídeos/administração & dosagem
Polietilenoglicóis/administração & dosagem
Prolina/administração & dosagem
Prolina/análogos & derivados
Proteínas Recombinantes/administração & dosagem
RNA Viral/genética
Resultado do Tratamento
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Ensaio Clínico
Estudo Multicêntrico
Responsável: BR1.1 - BIREME



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde